Mutagenesis vol. 19 no. 5 © UK Environmental Mutagen Society 2004; all rights reserved.
Analysis of microsatellite instability in children treated for acute lymphocytic leukemia with elevated HPRT mutant frequencies
1Department of Pediatrics, 2Department of Medical Biostatistics, 3Vermont Cancer Center and 4Department of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405, USA
Survival rates of children treated for cancer have increased dramatically over the last 25 years following the development of risk-directed multi-modality treatment protocols. As a result, there is a rapidly growing population of children and young adult cancer survivors in which the long-term genotoxic effects of chemotherapeutic intervention is unknown. We have previously observed that children treated for acute lymphocytic leukemia (ALL) have significantly increased somatic mutant frequencies (Mfs) (30- to 1300-fold higher) at the hypoxanthine-guanine phosphoribosyltransferase (HPRT) reporter gene in their non-malignant peripheral T cells compared with children at diagnosis or controls. In order to gain insight into the etiology of the observed dramatic increase in Mfs following antineoplastic therapy, we investigated the prevalence of microsatellite instability (MSI), reflective of a defect in DNA mismatch repair (MMR), in children with ALL at diagnosis, during and after chemotherapy and compared them with healthy age-matched controls. MSI analysis using five microsatellite markers was performed on 167 T cell isolates from 40 healthy children and on 842 T cell isolates from 50 patients treated for ALL. High-frequency MSI (MSI-high) was identified in 2 healthy children (5%) and in 2 of 20 ALL subjects at the time of disease recurrence (relapse) (10%). There was no statistically significant difference between the prevalence of MSI-high in patients at the time of ALL relapse and healthy children, nor between the children with ALL at other time points and healthy children. These data indicate that MMR defects, represented by MSI, are not a significant contributor to the elevated HPRT Mfs seen in children treated for ALL. However, in a small number of patients chemotherapy may play a role in the selection of cells with defects in MMR that may have long-term clinical implications.
5 To whom correspondence should be addressed at: Department of Pediatrics, E203 Given Medical Building, University of Vermont, 89 Beaumont Avenue, Burlington, VT 05405, USA. Tel: +1 802 656 2296; Fax: +1 802 656 2077; Email: barry.finette{at}uvm.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. J. Yang, D. Bhojwani, W. Yang, X. Cai, G. Stocco, K. Crews, J. Wang, D. Morrison, M. Devidas, S. P. Hunger, et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia Blood, November 15, 2008; 112(10): 4178 - 4183. [Abstract] [Full Text] [PDF]
|
|